Use of other medications with TUDORZA

Can be coadministered with commonly used COPD medications1
Short-acting beta2 agonists
:checkmark image:
:checkmark image:
Steroids (oral and inhaled)
:checkmark image:
Clinical studies showed no increase in adverse drug reactions
Cannot be coadministered with other anticholinergics1
Long-acting muscarinic antagonists
:x-mark image:
Short-acting muscarinic antagonists
:x-mark image:
Coadministration of TUDORZA with other anticholinergic drugs may lead to an increase in anticholinergic effects
  • No formal drug-interaction studies have been performed with TUDORZA1

Drug metabolism

  • TUDORZA is rapidly and extensively hydrolyzed to its alcohol and dithienylglycolic acid derivatives, which are inactive metabolites1
    • The absolute bioavailability of aclidinium bromide is approximately 6% in healthy volunteers
    • Not expected to alter the disposition of coadministered drugs metabolized by CYP450 enzymes, due to low plasma levels achieved

To read Important Safety Information about TUDORZA, visit Important Safety Information   


TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.


  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).
  • Inhaled medicines, including TUDORZA, may cause paradoxical bronchospasm. In addition, immediate hypersensitivity reactions may occur after administration of TUDORZA. If either of these occurs, treatment with TUDORZA should be stopped and other treatments considered.
  • TUDORZA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop.
  • Patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to TUDORZA. Use with caution in patients with severe hypersensitivity to milk proteins.
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA vs placebo, respectively.

Please also see the full Prescribing Information.